Esomeprazole Magenisium label

Esomeprazole Magenisium

Esomeprazole Magenisium Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

1.1 Treatment of Gastroesophageal Reflux Disease (GERD)

Healing of Erosive Esophagitis
Esomeprazole magnesium delayed-release capsules, USP are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules, USP may be considered.
Maintenance of Healing of Erosive Esophagitis
Esomeprazole magnesium delayed-release capsules, USP are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.
Symptomatic Gastroesophageal Reflux Disease
Esomeprazole magnesium delayed-release capsules, USP are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older.

1.2 Risk Reduction of NSAID-Associated Gastric Ulcer

Esomeprazole magnesium delayed-release capsules, USP are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.

1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

Esomeprazole magnesium delayed-release capsules, USP are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.

History

There is currently no drug history available for this drug.

Other Information

The active ingredient in the proton pump inhibitor esomeprazole magnesium delayed-release capsules, USP for oral administration is 1H-benzimidazole, 5-methoxy-2-[(S)-4-methoxy-3,5-dimethyl-2-pyridinyl]methyl]sulfinyl] magnesium dihydrate. Esomeprazole is S-enantiomer of omeprazole. (Initial U.S. approval of esomeprazole magnesium: 2001). Its molecular formula is C34H36MgN6O6S2.2H2O with molecular weight of 749.15 as a dihydrate. The structural formula is:
Figure 1

Structure

The magnesium salt is a white to slightly colored powder. It contains 2 moles of water of solvation and is slightly soluble in water. The stability of esomeprazole magnesium is a function of pH; it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions.
Esomeprazole magnesium is supplied in delayed-release capsules. Each delayed-release capsule contains 20 mg, or 40 mg of esomeprazole (present as 21.7 mg, or 43.5 mg esomeprazole magnesium dihydrate, USP) in the form of enteric-coated granules with the following inactive ingredients: glyceryl monostearate, hypromellose 2910, meglumine, methacrylic acid copolymer, methyl alcohol, methylene chloride, poloxamer 188, sodium hydroxide, sodium lauryl sulfate, sugar spheres, talc and triethyl citrate. The capsule shells have the following inactive ingredients: gelatin, FD & C Blue 1, D & C Red 28, FD & C Red 40, D & C Yellow 10, titanium dioxide and sodium lauryl sulfate.
The printing ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution and yellow iron oxide.

Esomeprazole Magenisium Manufacturers

  • Camber Pharmaceuticals, Inc.
    Esomeprazole Magenisium | Camber Pharmaceuticals, Inc.
    No Recall

    Esomeprazole Magenisium | Camber Pharmaceuticals, Inc.

    Esomeprazole Magenisium | Camber Pharmaceuticals, Inc.

    Esomeprazole magnesium is supplied as delayed-release capsules for oral administration. The recommended dosages are outlined in the Table 1. Esomeprazole magnesium delayed-release capsules should be taken at least one hour before meals.
    The duration of proton pump inhibitor administration should be based on available safety and efficacy data specific to the defined indication and dosing frequency, as described in the prescribing information, and individual patient medical needs. Proton pump inhibitor treatment should only be initiated and continued if the benefits outweigh the risks of treatment.
    Table 1: Recommended Dosage Schedule of Esomeprazole Magnesium Delayed-Release Capsules

    Indication
    Dose
    Frequency
    Gastroesophageal Reflux Disease (GERD)
    Healing of Erosive Esophagitis
    20 mg or 40 mg
    Once Daily for 4 to 8 Weeks*
    Maintenance of Healing of Erosive Esophagitis
    20 mg
    Once Daily**
    Symptomatic Gastroesophageal Reflux Disease
    20 mg
    Once Daily for 4 Weeks***
     
    Pediatric GERD
     
     
    12 to 17 Year Olds
     
     
    Healing of Erosive Esophagitis
    20 mg or 40 mg
    Once Daily for 4  to 8 Weeks
    Symptomatic GERD
    1 to 11 Year Olds+
    20 mg
    Once Daily for 4 Weeks
    Short-term Treatment of Symptomatic GERD
    10 mg
    Once Daily for up to 8 Weeks
    Healing of Erosive Esophagitis
     
     
    weight < 20 kg
    10 mg
    Once Daily for 8 Weeks
    weight > 20 kg
    10 mg or 20 mg
    Once Daily for 8 Weeks
    Risk Reduction of NSAID-
    Associated Gastric Ulcer
    20 mg or 40 mg
    Once Daily for up to 6 months**
    Pathological Hypersecretory ConditionsIncluding Zollinger­- Ellison Syndrome
    40 mg†
    ‡Twice Daily

    *[See Clinical Studies.(14.1).] The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4 to 8 weeks, an additional 4 to 8 weeks of treatment may be considered.
    **Controlled studies did not extend beyond six months.
    ***If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered.
    +Doses over 1 mg/kg/day have not been studied.
    †The dosage of esomeprazole magnesium delayed-release capsules in patients with pathological hypersecretory conditions varies with the individual patient. Dosage regimens should be adjusted to individual patient needs.
    ‡Doses up to 240 mg daily have been administered [see Drug Interactions (7)].
    Special Populations

    Hepatic Insufficiency
    In patients with mild to moderate liver impairment (Child Pugh Classes A and B), no dosage adjustment is necessary. For patients with severe liver impairment (Child Pugh Class C), a dose of 20 mg of esomeprazole magnesium delayed-release capsules should not be exceeded [see Clinical Pharmacology (12.3)].
    Directions for use specific to the route and available methods of administration for each of these dosage forms are presented in Table 2.
    Table 2: Administration Options


    Administration Options
    (See text following table for additional instructions.)
    Dosage Form
    Route
    Options
    Delayed-Release Capsules
    Oral
    Capsule can be swallowed whole.
    -or-
    Capsule can be opened and mixed with applesauce.
    Delayed-Release Capsules
    Nasogastric Tube
    Capsule can be opened and the intact granules emptied into a syringe and delivered through the nasogastric tube.

    Esomeprazole Magnesium Delayed-Release Capsules
    Esomeprazole magnesium delayed-release capsules should be swallowed whole.
    Alternatively, for patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the esomeprazole magnesium delayed-release capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately: do not store for future use. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The granules should not be chewed or crushed. If the granules/applesauce mixture is not used in its entirety, the remaining mixture should be discarded immediately.
    For patients who have a nasogastric tube in place, esomeprazole magnesium delayed-release capsules can be opened and the intact granules emptied into a 60 mL catheter tipped syringe and mixed with 50 mL of water. It is important to only use a catheter tipped syringe when administering esomeprazole magnesium delayed-release capsules through a nasogastric tube. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a nasogastric tube and deliver the contents of the syringe through the nasogastric tube into the stomach. After administering the granules, the nasogastric tube should be flushed with additional water. Do not administer the granules if they have dissolved or disintegrated.
    The mixture must be used immediately after preparation.